MedTrace Logo

BCG Vaccination to Protect Healthcare Workers Against COVID-19

NCT04327206 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 6828

Last updated 2024-09-19

No results posted yet for this study

Summary

Phase III, two-group multicentre, randomised controlled trial in up to 10 078 healthcare workers to determine if BCG vaccination reduces the incidence and severity of COVID-19 during the 2020 pandemic.

Conditions

  • Coronavirus Disease 2019 (COVID-19)
  • Respiratory Illness
  • Corona Virus Infection
  • COVID-19

Interventions

DRUG

BCG Vaccine

Freeze-dried powder: Live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331. Each 0.1 ml vaccine contains between 200000 to 800000 colony forming units. Adult dose is 0.1 ml given by intradermal injection

DRUG

0.9%NaCl

0.9% Sodium Chloride Injection

Sponsors & Collaborators

  • Royal Children's Hospital

    collaborator OTHER

  • Bill and Melinda Gates Foundation

    collaborator OTHER

  • Murdoch Childrens Research Institute

    lead OTHER

Principal Investigators

  • Prof Nigel Curtis · Murdoch Childrens Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-30
Primary Completion
2021-11-10
Completion
2022-05-27

Countries

  • Australia
  • Brazil
  • Netherlands
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04327206 on ClinicalTrials.gov